Welcome to our dedicated page for Ardent Health news (Ticker: ARDT), a resource for investors and traders seeking the latest updates and insights on Ardent Health stock.
Ardent Health, Inc. reports developments for a healthcare provider serving growing mid-sized urban communities in the United States. Through its subsidiaries, the company operates acute care hospitals and other sites of care across six states, with recurring updates centered on patient volume, admissions, net patient service revenue, adjusted EBITDA, cash flow, guidance, and balance-sheet priorities.
Company news also covers management presentations at healthcare investor conferences, operational-efficiency initiatives such as the IMPACT program, payer and Exchange market dynamics, and technology investments in virtual care. Recent operating updates include enterprise use of AI-assisted virtual nursing, patient observation, and patient-safety monitoring to support clinical workflows across inpatient settings.
Ardent Health (NYSE: ARDT), through Oklahoma Heart Institute (OHI), reports that OHI is the only site in Oklahoma and the surrounding region participating in several major national cardiovascular trials and is the first U.S. center to use the next-generation Supira percutaneous left ventricular assist device (pVAD) in the SUPPORT II clinical trial.
According to Ardent Health, OHI is evaluating emerging technologies for complex structural heart disease, including participation in the STAR Trial for a next-generation transcatheter aortic valve replacement (TAVR) system. OHI also served as the leading global enroller in the ENCIRCLE Trial, which supported FDA approval of the Edwards SAPIEN M3 transcatheter mitral valve replacement system in 2025. OHI is currently the only provider of this TMVR therapy in Oklahoma, reflecting Ardent Health’s strategy of expanding access to advanced, minimally invasive cardiovascular treatments through physician-led research and investment.
Ardent Health (NYSE: ARDT) reported second quarter 2026 revenue of $1.622 billion, down 1.4% year-over-year, with net income attributable to Ardent Health of $17 million ($0.12 per diluted share) versus $73 million ($0.52) a year earlier. Adjusted EBITDA declined 32.3% to $115 million, and net patient service revenue per adjusted admission fell 3.9%.
Adjusted admissions grew 2.5%, while admissions decreased 1.0% and total surgeries declined 2.9%. Operating cash flow rose 67% to $197 million. As of June 30, 2026, Ardent held $724 million in cash, $1.1 billion of total debt, net leverage of 0.8x, and available liquidity of $992 million. The company repurchased 1.4 million shares for $13 million, with $34 million remaining under its authorization.
Ardent reaffirmed full-year 2026 total revenue guidance of $6.4–$6.7 billion and Adjusted EBITDA guidance of $485–$535 million, while reducing net income and diluted EPS ranges. According to Ardent Health, its IMPACT program is now expected to generate at least $70 million of savings in 2026, up from $55 million previously.
Ardent Health (NYSE: ARDT) reported that its physicians and advanced practice providers have surpassed 1 million patient encounters supported by Ambience Healthcare’s ambient AI platform. Ardent-affiliated clinicians now use Ambience in 87% of ambulatory encounters across specialties, compared with industry benchmarks of roughly 40%–45% reported in studies.
According to Ardent Health, EHR data show providers save on average more than three hours per week on documentation. Since the enterprise-wide deployment in September 2025, Ambience has supported over 418,000 unique patients across Ardent’s ambulatory network, reflecting deeper integration of ambient AI into daily clinical workflows.
Ardent Health (NYSE: ARDT) will release its second quarter 2026 results after market close on Tuesday, August 4, 2026. A results conference call and webcast will follow on Wednesday, August 5, 2026 at 10 a.m. ET, accessible via the Investor Relations section at ir.ardenthealth.com. Live teleconference access is available at 1-888-596-4144 (North America toll-free) or 1-646-968-2525 (international), using access code 4437657. A replay will be available through August 19, 2026 at 1-800-770-2030 (North America toll-free) or 1-647-362-9199 (international), with the same access code.
Ardent Health (NYSE: ARDT) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, Florida, on June 10, 2026. Management will join a fireside chat at 11:20 a.m. ET, with a live audio webcast and replay available on the company’s investor relations website.
Ardent Health (NYSE: ARDT) appointed former COO Dave Caspers as President and CEO and to the Board, effective immediately, succeeding Marty Bonick. The leadership transition supports a strategy focused on operational excellence, growth, and care quality.
Ardent Health also reaffirmed full-year 2026 Adjusted EBITDA guidance of $485–$535 million, despite second-quarter volume softness, and is accelerating its company-wide IMPACT program to improve margins, performance, agility, and care transformation.
Ardent Health (NYSE: ARDT) is partnering with Fujifilm Healthcare Americas to deploy Synapse enterprise imaging across its acute care hospitals in six states. The unified Synapse Diagnostic PACS viewer and Synapse VNA will centralize radiology and cardiology imaging, streamline workflows, and support collaboration.
Integration with Epic’s EHR and Synapse Mobility will let clinicians access complete patient imaging records securely from any location and device, aiming to reduce data silos, ease documentation, and enable AI-supported imaging workflows and case prioritization.
Ardent Health (NYSE: ARDT) reported Q1 2026 results: total revenue $1.602B (+7.0% Y/Y), adjusted EBITDA $124M (+26.3% Y/Y; +15% ex-investment gain), and net income attributable $40M ($0.28 diluted). Adjusted admissions rose 2.0% while admissions fell 1.1%.
Balance sheet: $610M cash, $1.1B total debt, net leverage 1.0x, lease-adjusted net leverage 2.6x, available liquidity $0.9B. Company reaffirmed full-year 2026 guidance.
Ardent Health (NYSE: ARDT) will participate in the Bank of America 2026 Healthcare Conference on Wednesday, May 13, 2026, in Las Vegas. Management will hold a fireside chat on May 13 at 11:00 a.m. ET with a live audio webcast and a replay available on the company's Investor Relations website.
The management team will also be available for one-on-one investor meetings for conference registrants; contact Bank of America sales or investor.relations@ardenthealth.com for scheduling.
Ardent Health (NYSE: ARDT) will release first quarter 2026 results after market close on May 5, 2026. A conference call is scheduled for May 6, 2026 at 10:00 a.m. ET to review results and hold Q&A.
A webcast and presentation materials will be available in the Investor Relations section at ir.ardenthealth.com. Participants should register at least 15 minutes early. Dial-in and international access codes are provided; a teleconference replay is available through May 20, 2026.